ALK-Abello’s Pharmalgen Wins U.K. Cost-Agency Backing for Stings

ALK-Abello A/S’s Pharmalgen won the preliminary backing of the U.K.’s health-cost agency for the treatment of severe reactions to bee and wasp stings.

As many as nine people die every year in the U.K. from allergic reactions, known as anaphylaxis, to the stings, the National Institute for Health and Clinical Excellence said in an e-mailed statement. Pharmalgen, an injection, prevents the reaction by desensitizing the immune system, said the agency, known as NICE.

A final decision probably will be made by February, NICE said. ALK-Abello is based in Hoersholm, Denmark.

Before it's here, it's on the Bloomberg Terminal. LEARN MORE